PMLI
AIMT

Penn Mutual Life Insurance’s Aimmune Therapeutics AIMT Stock Holding History

Penn Mutual Life Insurance’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-19,000
Closed -$401K – 23
2017
Q3 		$401K Sell
19,000
-20,000
-51% -$431K 0.27% 22
2017
Q2 		$801K Hold
39,000
– – 0.7% 19
2017
Q1 		$934K Hold
39,000
– – 0.86% 19
2016
Q4 		$797K Buy
+39,000
New +$797K 0.65% 21

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Penn Mutual Life Insurance's AIMT Position: Q4 2017 in Review

Penn Mutual Life Insurance sold out of Aimmune Therapeutics (AIMT) in Q4 2017, closing a stake of 19,000 shares — an estimated $401K sold.

Penn Mutual Life Insurance first reported a position in AIMT in Q4 2016 and held it in 4 quarters. The position peaked at $934K in Q1 2017. 129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

  • Penn Mutual Life Insurance reported no remaining Aimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Penn Mutual Life Insurance sold 19,000 Aimmune Therapeutics shares in Q4 2017, an estimated $401K.
  • Penn Mutual Life Insurance first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 4 quarters.
  • Penn Mutual Life Insurance's Aimmune Therapeutics position peaked at $934K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on Penn Mutual Life Insurance's 13F filing for Q4 2017, filed 12 Feb 2018.